Metraipolis › archive › dc_724af0bb1bda

Three-year longitudinal assessment of denosumab's efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study — Europe PMC PMID:42523737

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42523737
DOI
10.3389/fmed.2026.1825383
License (as archived)
solo-consultazione
Archived
2026-10-18T07:02:23.992Z
SHA-256 of the archived text
53def45f04e05c7f219eedde5de6262f546cb6c74e948d41f659fa2a58498b57
Stable URL of this page
https://metraipolis.com/documento/dc_724af0bb1bda

How to cite

Three-year longitudinal assessment of denosumab's efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study — Europe PMC PMID:42523737 — Europe PMC (en), https://europepmc.org/article/MED/42523737 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_724af0bb1bda (Metraipolis archive dc_724af0bb1bda, sha256 53def45f04e05c7f219eedde5de6262f546cb6c74e948d41f659fa2a58498b57)
BibTeX
@misc{dc724af0bb1bda,
  title = {Three-year longitudinal assessment of denosumab's efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study — Europe PMC PMID:42523737},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42523737},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_724af0bb1bda; sha256 53def45f04e05c7f219eedde5de6262f546cb6c74e948d41f659fa2a58498b57},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42523737. Agents can read the archived copy with the MCP tool read_document.